ESR1 and cancer: In a study by Boers et al. [105], [18F]FDG PET/CT monitored the effect of endocrinological therapy coupled with cyclin-dependent kinase (CDK) inhibitors (a family of drugs that prevents overgrowth of cancer cells) in metastatic ER + BC at baseline and after 8 weeks.